06 January 2020 | News
Griffith University has signed the exclusive licence and co-development agreement with China Grand Pharma
Australia based Griffith University’s Institute for Glycomics has partnered with Hong Kong listed China Grand Pharma’s newly established Australian company Grand Medical Ltd to develop a new drug for Human Parainfluenza Virus.
Griffith University has signed the exclusive licence and co-development agreement with China Grand Pharma to co-develop and commercialise the human parainfluenza drug candidate globally. The deal comprises significant upfront Research & Development and licence fees plus development and sales milestone fees with a tiered royalty on product sales.
The Institute’s General Manager and Chair of Ausbiotech Ltd Queensland branch, Dr Chris Davis, led the Institute’s Business team in commercialisation negotiations with China Grand Pharma.
Human parainfluenza virus (hPIV) commonly causes upper and lower respiratory illnesses in infants, young children, the elderly, and people with weakened immune systems, including transplant patients, however anyone can get infected. Symptoms of severe lower respiratory illness can include bronchitis, bronchiolitis, croup and pneumonia.
Professor Mark von Itzstein AO, Director of the Institute for Glycomics and leader of the research team that discovered the world’s first drug for Influenza, Relenza, is the lead researcher and co-inventor of this new scientific discovery.